Overview
VIR market data
Price History
VIR price chart · 3M
- O
- 10.97
- H
- 11.45
- L
- 10.87
- C
- 11.28
- Vol
- 99,739.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $10.97
- Previous Close
- $11.10
- Day High
- $11.45
- Day Low
- $10.87
- 52 Week High
- $11.45
- 52 Week Low
- $8.17
- 7 Day Return
- +22.41%
- 30 Day Return
- +27.46%
- 90 Day Return
- +18.36%
- 1 Year Return
- +11.79%
- Daily Notional Volume
- $1.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -41.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.35 – $11.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 1.10 · P/S 4.95.
Company News
Vir Biotechnology shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 6, 2026, 12:54 PM
Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M EstimateBenzinga · Aug 5, 2026, 8:15 PM
Vir Biotechnology Appoints Brent Sabatini To Interim Principle Financial Officer Effective July 23 As The Company Begins Search For CFOBenzinga · Jul 24, 2026, 12:32 PM
8-K filing — Vir Biotechnology, Inc. (VIR)SEC EDGAR · Jul 24, 2026, 12:31 PM
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27Benzinga · Jun 11, 2026, 12:30 PM